Merck Sees $70 Billion Pipeline Boost and Beats Q4 2025 Estimates
Merck beat fourth-quarter 2025 earnings and sales estimates and projects over $70 billion in mid-2030s pipeline opportunities—more than double prior Keytruda consensus of $35 billion. Capvaxive, Winrevair, Welireg and Ohtuvayre generated $759 million, $1.4 billion, $716 million and $178 million in 2025 sales, supporting a diversified post-Keytruda growth strategy.
1. Fourth-Quarter 2025 Outperformance
Merck reported fourth-quarter 2025 earnings and sales above street estimates, boosting investor confidence. Management cited strong performance across key products as foundation for its optimistic long-term outlook.
2. Post-Keytruda Pipeline Opportunity
Merck projects over $70 billion in non-risk-adjusted commercial opportunities by mid-2030s, more than double the prior $35 billion consensus peak for Keytruda in 2028 and $20 billion above last year’s forecast.
3. New Launches Driving Growth
Capvaxive, Winrevair, Welireg and Ohtuvayre generated $759 million, $1.4 billion, $716 million and $178 million in 2025, respectively, highlighting the potential of its enhanced respiratory and oncology portfolios.
4. M&A and Valuation Outlook
The company’s phase III pipeline has almost tripled since 2021 through in-house progress and acquisitions including Verona and Cidara, underpinning a forward P/E of 18.77 versus 18.83 for peers and shares up 44.1% over six months.